Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

Phase 1positiveBisphosphocin® Nu-8Positive

AI Analysis

Summary

Lakewood-Amedex Biotherapeutics announced positive preclinical data showing Bisphosphocin® Nu-8 achieved up to 97% inhibition of E. coli growth in rodent models of urinary tract and pulmonary infections. The compound is being evaluated for intravesical administration.

Outcome Details

Intravesical administration of Bisphosphocin® Nu-8 demonstrated up to 97% inhibition of E. coli growth compared to vehicle control in rodent models

Importance:4/10

Sentiment:

0.75

preclinical dataE. coliurinary tract infectionpulmonary infectionin vivo efficacy

Related Companies

$LABT

Read the original article

Published by PR Newswire Biotech on October 7, 2026 12:02 PM

Read Original